Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicaments and methods to treat autoimmune disease and cancer

A technology for autoimmunity and diseases, applied in diseases, allergic diseases, metabolic diseases, etc., can solve problems such as weak effects

Inactive Publication Date: 2010-03-31
DIAMYD THERAPEUTICS
View PDF0 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, several approaches to preserving residual β-cell function have been tried, with the exception of treatment with anti-CD3 monoclonal antibodies (which appears to be very promising although many patients have adverse effects) 16，17 ), the remaining methods have only minimal or too weak effects 6-15

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicaments and methods to treat autoimmune disease and cancer
  • Medicaments and methods to treat autoimmune disease and cancer
  • Medicaments and methods to treat autoimmune disease and cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0057] [054] With the foregoing summary in mind, the following presents a detailed description of the preferred embodiment (presently believed to be the best mode) of the invention.

[0058] [055] The invention is further understood from the following patient studies.

[0059] method

[0060] [056] This study was approved by the Research Ethics Committee of Linkoping University in Sweden and the Swedish regulatory authorities.

[0061] Research design

[0062] [057] In 8 pediatric clinics in Sweden, the presence of GAD65 autoantibodies (GADA) and fasting C-peptide levels greater than 0.1 pmol / ml were associated with 10-18 year olds who had shown disease within the preceding 18 months. T1D patients were screened. A total of 70 patients were eligible and were randomized to receive 20 μg of recombinant human GAD65 formulated in alum ( Double-blind treatment of Diamyd Medical, Stockholm, Sweden, 35 patients) or placebo (same formulation without rhGAD65; 35 patients).

[0063...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to methods and formulations for GAD- vaccination to evoke a systemic effect rather that a GAD-specific effect. The present invention may therefore be used in the treatment of disease in humans not bearing on a GAD-specific effect. The invention includes a method to treat an autoimmune disease or disorder by administering at least one sequestered autoantigen in a primeand boost regimen for sensitization purposes followed by a boost for treatment purposes. This may be done upon diagnosis. Examples of sequestered autoantigens include: GAD65, GAD67, Pro-Insulin, Basic Myelin Protein, MOG and Chondrotoin II. The present invention relates to medications and methods for treatment of autoimmune disease within six months from diagnosis.

Description

[0001] inventor [0002] Johnny Ludvigsson, Rosaura Casas, Maria , Anders Essen-Moller [0003] Cross References to Related Applications [0004] [001] This application claims priority to U.S. Provisional Application No. 60 / 926,121, filed April 24, 2007, and U.S. Provisional Application No. 60 / 993,640, filed September 13, 2007. Background technique [0005] [002] Autoimmune diseases, allergic reactions, and cancer are diseases associated with immune inflammation that is dysregulated in equal and different ways. Some autoimmune disease and tissue rejection mechanisms are organ-specific, most are T cell-mediated and triggered by environmental factors, including viral infection in susceptible individuals. This can lead to the exposure of cryptic self-antigens (self-cryptic antigens) or grafted antigens, which can be used to therapeutically modulate the disease. Hypersensitivity reactions are often associated with B cell-mediated IgE responses to repeated allergen exposure. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/51A61P3/10A61P37/02A61P5/50
CPCA61K2039/55505A61K39/0008A61P1/04A61P1/16A61P1/18A61P11/00A61P11/02A61P11/06A61P13/02A61P13/08A61P15/02A61P17/00A61P17/02A61P17/04A61P19/02A61P21/04A61P25/28A61P29/00A61P3/10A61P35/00A61P37/00A61P37/02A61P37/06A61P37/08A61P5/14A61P5/50A61P7/06A61P9/10A61K38/28A61K39/00
Inventor J·路德维格森R·卡萨斯M·法瑞舍A·伊森-摩勒
Owner DIAMYD THERAPEUTICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com